Insulet (PODD)

• Market cap: $19.3B
• 1 day: 1.08%
• 5 days: 1.65%
• 1 month: 4.73%
• 3 months: 20.37%
• 6 months: 39.54%
• Year to date: 7.38%
• 1 year: 37.29%
• 5 years: 46.12%
• 10 years: 720.13%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Employees: 3,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

42% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 64

13% more capital invested

Capital invested by funds: $14.4B [Q2] → $16.4B (+$1.92B) [Q3]

3% more funds holding

Funds holding: 589 [Q2] → 609 (+20) [Q3]

5% less repeat investments, than reductions

Existing positions increased: 220 | Existing positions reduced: 232

1.46% less ownership

Funds ownership: 102.17% [Q2] → 100.72% (-1.46%) [Q3]

29% less call options, than puts

Call options by funds: $163M | Put options by funds: $229M

75% less funds holding in top 10

Funds holding in top 10: 8 [Q2] → 2 (-6) [Q3]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $234 15% downside
• Avg. target: $299 9% upside
• High target: $330 20% upside

9 analyst ratings

• positive: 8 89%
• neutral: 1 11%
• negative: 0 0%

TD Cowen Joshua Jennings 43% 1-year accuracy 9 / 21 met price target	17% upside $324	Buy Maintained	3 Jan 2025
JP Morgan Robbie Marcus 62% 1-year accuracy 13 / 21 met price target	20% upside $330	Overweight Maintained	12 Dec 2024
Citigroup Joanne Wuensch 60% 1-year accuracy 28 / 47 met price target	12% upside $310	Buy Maintained	11 Dec 2024
Wells Fargo Lawrence Biegelsen 0% 1-year accuracy 0 / 2 met price target	11% upside $305	Overweight Maintained	11 Dec 2024
Canaccord Genuity William Plovanic 72% 1-year accuracy 34 / 47 met price target	10% upside $304	Buy Maintained	9 Dec 2024